Nucleic acid aptamers for cardiovascular therapeutics

RNA Technologies in Cardiovascular Medicine and Research

Volumn , Issue , 2008, Pages 289-297

  Pendergrast, P S ^a   Thompson, K M ^a   Schaub, R G ^a  

^a Archemix Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950829515     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-78709-9_14     Document Type: Chapter

References (40)

1. Bock LC, Griffin LC, Latham JA et al (1995) Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355:564-566.
2. Burmeister PE, Wang C, Killough J R et al (2006) 2′-Deoxy purine, 2′-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics. Oligonucleotides 16(4):337-351.
3. Boncler MA, Koziolkiewicz M, Watala C (2001) Aptamer inhibits degradation of platelet proteolytically activatable receptor, PAR-1, by thrombin. Thromb Res 104:215-222.
4. Chyu K-Y, Shah PK (2007) Choking off plaque neovascularity: A promising atheroprotective strategy or a double-edged sword? Arterioscl Thromb Vasc Biol 27:993-995.
5. Cload ST, McCauley TG, Keefe AD et al (2006) Properties of therapeutic aptamers. In: Klussman S (ed) The aptamer handbook. Wiley, Weinheim, pp 363-416.
6. Dougan H, Lyster DM, Vo CV et al (2000). Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl Med Biol 27:289-297.
7. Doyle B, Caplice N (2007) Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 49:2102-2104.
8. Dyke CK, Steinhubl SR, Kleiman NS et al (2006) First-in-human experience of an antidotecontrolled anticoagulant using RNA aptamer technology. A Phase Ia pharmacodynamic evaluation of a drug-antidote paior for the controlled regulation of factor IXa activity. Circulation 114:2490-2497.
9. Eyetech Study Group (2003). Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology 110:979-986.
10. Furie B, Furie B (2007) In vivo thrombosis. J Thromb Haemost Suppl 1:12-17.
11. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM et al (2007) Pharmacokinetis, pharmacodynamics, and safety of an anti-von Willebrand factor therapeutic aptamer, ARC1779, in healthy volunteers. Circulation 116:2678-2686.
12. Green LS, Jellinek D, Bell C et al (1995) Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 2:683-695.
13. Griffin LC, Tidmarsh GF, Bock LC et al (1993) In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81:3271-3276.
14. Healy JM, Lewis SD, Kurz M et al (2004) Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res 21:2234-2246.
15. Hennan JK, Swillo RE, Morgan GA et al (2006) Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis. Thromb Haemost 95:469-475.
16. Huang J, Moore J, Soffer S et al (2001) Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J Pediatr Surg 36:357-361.
17. Hutabarat R, Horvath C, Funk WD (2007) Discovery of a potent, direct thrombin inhibiting aptamer, J Thromb Haemost 5(Suppl 2):P-S-067.
18. Italiano JE, Richardson JL, Patel-Hett S Et al (2008) Angiogenesis is regulated by a novel mechanism: Pro- And anti-angiogenic proteins are organized into separate platelet a-granules and differentially released. Blood 111(3):1227-1233 (published ahead of print On-Line October 25, 2007).
19. Jenison RD, Jennings SD, Walker DW et al (1998) Oligonucleotide inhibitors of P-selectindependent neutrophil-platelet adhesion. Antisense Nucleic Acid Drug Dev 8:265-279.
20. Kahlon R, Shapero J, Gotlieb AI (1992) Angiogenesis in atherosclerosis. Can J Cardiol 8:60-64.
21. Kolodgie FD, Narulo J, Yuan C et al (2007) Elimination of neoangiogenesis for plaque stabilization: Is there a role for local drug therapy? J Am Coll Cardiol 49:2093-2101.
22. Lagassé HAD, Merlino PG, Marsh HN et al (2007) Discovery and characterization of a potent neutralizing anti-VWF A1 domain specific aptamer. J Thromb Haemost 5(Suppl 2):P-S-665.
23. Leppanen O, Janjic N, Carlsson M-A et al (2000) Intimal hyperpasia recurs after removal of PDGF-AB and BB inhibition by the rat carotid artery injury model. Arterioscl Thromb Vasc Biol 20:89-95.
24. Li W-X, Kaplan AV, Grant GW et al (1994) A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. Blood 83:677-682.
25. Michel JB, Thaunat O, Houard X, et al. (2007) Topological determinants and consequences of adventitial responses to arterial wall injury. Arterioscler Thromb Vasc Biol 27:1259-1268.
26. Ng EWM, Adamis AP (2006) Anti-VEGF aptamer (pegaptanib) yherapy for ocular vascular diseases. Oligonucleotide thrapeutics: First Annual Meeting of the Oligonucleotide Therapeutics Society. Ann NY Acad Sci 1082:151-171.
27. Nimjes SM, Keys JR, Pitoc GA et al (2006) A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther 24:408-415.
28. Nishimura JI, Burnette AD, Oney S et al (2007) Blood 110(11): Abstract 147.
29. Oney S, Nimjee SM, Layzer J et al (2007) Antidote-Controlled Platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides 17:265-274.
30. Ostendorf T, Kunter U, Grone HJ et al (2001). Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 12:909-918.
31. Paborsky LR, McCurdy SN, Griffin LC et al (1993) The single stranded DNA aptamer-binding site of human thrombin. J Biol Chem 268:20808-20811.
32. Petrovan PJ, Kaplan CD, Reisfeld RA et al (2007) DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscl Thromb Vasc Biol 27:1095-1100.
33. Rottman RB, Gilbert M, Marsh HN et al (2007) An anti-Von Willebrand's factor A1 domain aptamer inhibits arterial thrombosis induced by electrical injury in cynomolgus macaques. J Thromb Haemost 5(Suppl 2):P-S-664.
34. Rusconi CP, Yeh A, Lyerly HK et al (2000) Blocking the initiation of coagulation by RNA aptamers to Factor VIIa. Thromb Haemost 84:841-848.
35. Rusconi CP, Roberts JD, Pitoc GA et al (2004a) Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 22:1423-1428.
36. Rusconi CP, Scardino E, Layzer J et al (2004b) RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419:90-94.
37. Sarraf-Yazdi S, Mi J, Moeller BJ et al (2007) Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin-2 specific RNA aptamer. J Surg Res (published on-line Oct 22 2007).
38. Sennino B, Falcon BL, McCauley D et al (2007) Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 67:7358-7367.
39. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510.
40. Wagner-Whyte J, Khuri SF, Preiss JR et al (2007) Discovery of a potent, direct thrombin inhibiting aptamer. J Thromb Haemost 5(Suppl 2):P-S-067.